Catalyst Wire Dossier Catalyst Wire Dossier

Pinatuzumab Vedotin (DCDT2980S)

pinatuzumab vedotin · Genentech, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Pinatuzumab Vedotin (DCDT2980S), covering 2018-04-19 to 2018-04-19. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) [Phase 1, Phase 2]

See pricing